MedPath

Cystoscopic Ablation Via RF Energy Clinical Trial

Phase 1
Terminated
Conditions
Overactive Bladder
Interventions
Device: Amphora OAB Device
Registration Number
NCT02398578
Lead Sponsor
Amphora Medical, Inc.
Brief Summary

Phase I/II study to assess the safety and performance of the Amphora OAB system for treatment of urgency and frequency with or without urge incontinence caused by an overactive bladder.

Detailed Description

The study will enroll subjects with symptomatic idiopathic overactive bladder (OAB).

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
63
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Amphora OAB DeviceAmphora OAB DeviceSpecialized cystoscope that facilitates visualization and radiofrequency (RF) therapy for the treatment of OAB.
Primary Outcome Measures
NameTimeMethod
Device-related complications through 24 month follow-up24 month
Secondary Outcome Measures
NameTimeMethod
Procedural SuccessDuring the study procedure
Change from Baseline of Quality of Life Scores4 weeks, 12 weeks, 6, 12, 18, and 24 months
Device Technical SuccessDuring the study procedure

Trial Locations

Locations (4)

University of Antwerp

🇧🇪

Antwerp, Belgium

University of Calgary

🇨🇦

Calgary, Alberta, Canada

University Hospital Ghent

🇧🇪

Ghent, Belgium

University of Sherbrooke

🇨🇦

Sherbrooke, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath